CBD Oil: Documented Drug Interactions
If you take CBD oil and any prescription medication, an interaction is possible. CBD inhibits enzymes in the family that processes most prescription drugs, and the European Food Safety Authority (EFSA) could not establish safety for people taking any medication.
Key Takeaways
- ✓CBD inhibits CYP3A4 and CYP2C19, two major drug-metabolizing enzymes, producing what pharmacologists call the "grapefruit effect."
- ✓The warfarin interaction is documented: a marked INR rise was reported in a case report, and INR monitoring is advised when CBD is started or stopped.
- ✓Clinical data from prescription cannabidiol trials show that CBD increases blood levels of clobazam's active metabolite by up to five-fold, and can elevate liver enzymes when combined with valproate.
- ✓CBD's enzyme inhibition is dose-dependent, but low doses have not been shown to be free of interaction risk. EFSA (2025) set a provisional safe intake of about 2 mg/day for healthy adults and could not establish safety for people taking any medication.
- ✓CBD can add to the sedation of alcohol, benzodiazepines and opioids, has been linked to liver enzyme rises, and is not recommended in pregnancy or breastfeeding.
- ✓Full-spectrum CBD products contain variable amounts of THC, which introduces additional interaction considerations beyond CBD alone.
- ✓The CBD market remains inconsistently regulated, and third-party testing is essential for verifying that a product contains what the label claims.
1. How CBD Interacts With the CYP450 System
To understand why CBD interacts with so many medications, it helps to know a little about the system the body uses to break down drugs. The cytochrome P450 (CYP450) family of enzymes, found primarily in the liver and the lining of the small intestine, is responsible for metabolizing an estimated 60 to 80 percent of all clinically used medications. When you swallow a pill, these enzymes go to work breaking it down into metabolites that the body can use or eliminate. The speed of that process determines how much active drug circulates in your bloodstream and for how long.
CBD is a significant inhibitor of two CYP450 enzymes in particular: CYP3A4 and CYP2C19. CYP3A4 is the single most abundant drug-metabolizing enzyme in the human body, responsible for processing roughly half of all prescription drugs. CYP2C19 handles a smaller but clinically important subset, including certain anti-seizure medications, proton pump inhibitors, and the anti-platelet drug clopidogrel. When CBD occupies these enzymes, it slows down their ability to process other substances, and blood levels of co-administered drugs can rise.
Pharmacologists often describe this as the "grapefruit effect" because grapefruit juice inhibits CYP3A4 through a very similar mechanism. If you have ever seen a medication label warning you not to consume grapefruit, CBD acts on the same enzymatic pathway. The key difference is that while a glass of grapefruit juice produces relatively modest and transient enzyme inhibition, CBD (particularly at higher doses) can produce more sustained effects. Research published in Drug Metabolism and Disposition has demonstrated that CBD acts as a potent, competitive inhibitor of CYP3A4 and a mechanism-based (irreversible) inhibitor of CYP2C19, meaning it can permanently deactivate individual enzyme molecules, requiring the body to synthesize new ones.
CBD also inhibits CYP2C9 (which metabolizes warfarin and certain NSAIDs), CYP2D6 (which processes many antidepressants and beta-blockers), and several UDP-glucuronosyltransferases (UGTs) involved in Phase II metabolism. The breadth of enzyme involvement helps explain why the list of potential interactions is so extensive. In vitro studies consistently show inhibition across multiple CYP isoforms, though the clinical significance varies depending on the CBD dose and the specific drug in question.
2. Blood Thinner Interactions: The Warfarin Evidence
The interaction between CBD and warfarin is one of the better-documented ones in the cannabinoid literature, though mainly through case reports, and it deserves particular attention because of its potential severity. Warfarin is metabolized primarily by CYP2C9, with secondary contributions from CYP3A4 and CYP1A2. When CBD inhibits these enzymes, warfarin is cleared from the body more slowly, its blood levels rise, and its anticoagulant effect intensifies. The clinical marker for this is the International Normalized Ratio (INR), which measures how long it takes blood to clot.
A 2018 case report published in Epilepsy & Behavior Case Reports (Grayson et al.) described a patient on stable warfarin therapy in whom a marked INR rise was reported as the CBD dose was increased, requiring a reduction in the warfarin dose. Evidence beyond case reports is limited, but the pharmacokinetic (how the body processes the drug) mechanism is plausible, and interaction references advise INR monitoring when CBD is started, stopped or changed in people taking warfarin.
Beyond warfarin, CBD may also interact with direct oral anticoagulants (DOACs) such as apixaban andrivaroxaban, both of which are CYP3A4 substrates. While clinical data on these newer combinations remains limited, the pharmacological basis for concern is solid, and some practitioners recommend caution for patients on any anticoagulant therapy who wish to use CBD.
3. Anti-Seizure Medication Interactions: Prescription Cannabidiol Data
The richest clinical data on CBD drug interactions comes from the prescription cannabidiol development program, because gaining regulatory approval required extensive pharmacokinetic studies. These trials, conducted in patients with severe epilepsy syndromes (Dravet syndrome and Lennox-Gastaut syndrome), provide the most rigorous evidence available on how CBD behaves when combined with other drugs in a controlled setting.
Clobazam: The Most Clinically Significant Interaction
Clobazam is a benzodiazepine commonly used in the treatment of refractory epilepsy. It is metabolized by CYP2C19 into its active metabolite, N-desmethylclobazam, which is itself pharmacologically active and contributes substantially to the drug's therapeutic (and side) effects. Because CBD potently inhibits CYP2C19, co-administration produces dramatic increases in N-desmethylclobazam levels.
Clinical data from the prescription cannabidiol program showed that CBD increased plasma levels of N-desmethylclobazam by up to about 500% (a five-fold increase). In adults, sedation was more frequent with higher N-desmethylclobazam levels, and clobazam doses were reduced in some patients. The prescribing information advises considering a clobazam dose reduction if sedation occurs.
Valproate: Liver Enzyme Elevation
Valproate is a broad-spectrum anti-seizure medication that carries its own hepatotoxic (potentially harmful to the liver) potential. During prescription cannabidiol clinical trials, researchers observed that patients taking both CBD and valproate developedelevated liver transaminases (ALT and AST) at substantially higher rates than those not taking valproate.
The mechanism appears to involve a complex interplay between CBD, valproate, and their respective metabolic pathways. The label lists liver injury as a warning, and liver tests are required before and during treatment, particularly in patients receiving concomitant valproate.
Other Anti-Seizure Medications
In an open-label study (Gaston et al., 2017), serum levels of topiramate and rufinamiderose with increasing CBD dose, and in adults so did zonisamide and eslicarbazepine. Apart from clobazam and its metabolite, the mean changes stayed within the accepted therapeutic range, but they illustrate the breadth of CBD's inhibitory effects across the CYP450 system.
4. Antidepressant Interactions
The interaction between CBD and antidepressants has received less rigorous clinical study than the anti-seizure data, but the pharmacological basis for concern is clear. Many commonly prescribed antidepressants are metabolized by enzymes that CBD inhibits, and there are pharmacodynamic considerations as well.
SSRIs: Citalopram, Escitalopram, and Sertraline
Selective serotonin reuptake inhibitors are among the most widely prescribed medications in the world, and several are metabolized by enzymes that CBD affects. Citalopram and escitalopram are primarily metabolized by CYP2C19 and CYP3A4, placing them squarely in CBD's inhibitory range. If CBD slows the metabolism of these drugs, their blood levels could rise, potentially amplifying both therapeutic effects and side effects such as nausea, dizziness, insomnia, and in rare cases, QT prolongation (a heart rhythm concern particularly relevant to citalopram at higher plasma concentrations).
Sertraline is metabolized in part by CYP2C19 and CYP2D6, so its levels could also rise.Fluoxetine and paroxetine are CYP2D6 substrates and also inhibit CYP2D6 themselves, creating a complex scenario when layered with CBD's own CYP2D6 inhibition.
Tricyclics and Other Antidepressants
Tricyclic antidepressants like amitriptyline and nortriptyline are metabolized by CYP2D6 and CYP2C19 and have narrow therapeutic windows, meaning even modest increases in blood levels can produce noticeable and sometimes uncomfortable side effects including dry mouth, sedation, constipation, and cardiac conduction changes. CBD's inhibition of these enzymes could raise tricyclic levels, and some practitioners advise therapeutic drug monitoring if the combination is being used.
It is worth noting that CBD also has its own pharmacodynamic effects on serotonin signaling. Preclinical research suggests CBD acts as an agonist at the 5-HT1A serotonin receptor, which may partially explain its anxiolytic properties. This adds a layer of complexity when CBD is combined with serotonergic (affecting serotonin levels) medications.
5. Blood Pressure Medication Interactions
CBD has been shown in several clinical studies to modestly lower blood pressure on its own. A 2017 randomized, placebo-controlled crossover study published in JCI Insight found that a single 600 mg dose of CBD reduced resting systolic blood pressure by approximately 6 mmHg compared to placebo. This becomes more relevant when CBD is combined with prescription antihypertensives.
Calcium channel blockers such as amlodipine, felodipine, and nifedipineare CYP3A4 substrates. CBD's inhibition of CYP3A4 could slow their metabolism and raise blood levels, producing a dual mechanism for enhanced blood pressure lowering: both the pharmacokinetic interaction (higher drug levels) and the pharmacodynamic interaction (CBD's own hypotensive effect). The result could be excessive blood pressure reduction, leading to dizziness, lightheadedness, or fainting, especially upon standing.
Beta-blockers metabolized by CYP2D6, including metoprolol and propranolol, could also see elevated levels when combined with CBD. Excessive beta-blockade can produce bradycardia (slow heart rate), fatigue, and exercise intolerance. While clinical case reports specifically involving CBD and beta-blockers remain scarce, the pharmacological basis is well-established.
What practitioners typically consider: For individuals on blood pressure medications who wish to use CBD, some healthcare providers suggest starting with low CBD doses, monitoring blood pressure more frequently during the initial period, and watching for symptoms of hypotension. This is particularly relevant for older adults, who are more susceptible to falls from orthostatic hypotension.
6. Immunosuppressant Interactions
Immunosuppressant medications represent one of the highest-stakes categories for drug interactions, because the consequences of altered blood levels can be severe in both directions. Too little immunosuppression and an organ transplant recipient risks rejection. Too much, and the patient faces dangerous vulnerability to infections and malignancies.
Tacrolimus and cyclosporine are both extensively metabolized by CYP3A4 and have notoriously narrow therapeutic windows. CBD's inhibition of CYP3A4 could elevate blood levels of these drugs, potentially pushing them into the toxic range. A 2019 report in the American Journal of Transplantation(Leino et al.) described a participant in a CBD epilepsy trial whose dose-normalized tacrolimus levels rose about three-fold while taking high-dose prescription cannabidiol.
Sirolimus and everolimus are similarly dependent on CYP3A4 metabolism. The interaction potential with CBD is analogous to that of tacrolimus and cyclosporine, and the clinical consequences of elevated levels (nephrotoxicity, myelosuppression) are equally concerning.
What practitioners typically consider: Transplant medicine teams generally advise extreme caution with any supplement that affects CYP3A4, and CBD falls squarely into that category. If an organ transplant recipient is determined to use CBD, many transplant centers recommend frequent trough level monitoring of the immunosuppressant and close communication with the transplant team throughout.
7. Sedation, Liver Effects, and Pregnancy
Additive sedation. Sleepiness is one of the most common side effects of CBD in trials. Combined with alcohol, benzodiazepines, opioids, sleep medicines or sedating antihistamines, the sedative effects can add up. Be careful with driving and anything that requires alertness.
Liver effects. Rises in liver enzymes, and liver injury, have been reported with CBD, especially at the high doses used in epilepsy and with valproate. EFSA's review of CBD as a novel food identified effects on the liver among its concerns. Seek medical advice if you notice jaundice, dark urine, or upper abdominal pain.
Pregnancy and breastfeeding. EFSA could not establish safety in pregnancy or breastfeeding, and CBD is not recommended during either.
8. The THC Question: Full Spectrum vs. Isolate
Not all CBD products are created equal, and the distinction between product types matters for drug interaction risk.CBD isolate contains only cannabidiol, with no other cannabinoids present.Broad-spectrum products contain CBD plus other minor cannabinoids and terpenes but with THC removed (or reduced to undetectable levels). Full-spectrum products contain CBD, other cannabinoids, terpenes, and up to 0.3% THC (the legal limit under the 2018 Farm Bill in the United States).
This distinction matters because THC (delta-9-tetrahydrocannabinol) is itself a CYP3A4 substrate and a CYP1A2 inducer, meaning it adds its own layer of pharmacokinetic complexity. While the amount of THC in a legal full-spectrum product is small, it is not pharmacologically zero. THC also has its own pharmacodynamic effects, including sedation, psychoactivity, and cardiovascular effects (transient tachycardia), that can interact additively with certain medications.
For individuals taking medications with narrow therapeutic windows (such as warfarin, immunosuppressants, or anti-seizure drugs), some practitioners view CBD isolate as the more predictable choice, simply because it removes the variable of THC and other cannabinoids from the equation. That said, the enzyme inhibition potential of CBD itself remains regardless of the product formulation.
There is also the matter of the "entourage effect," a concept suggesting that cannabinoids and terpenes work synergistically when present together. Some researchers and users believe full-spectrum products offer greater therapeutic benefit. The evidence for this remains preliminary and debated, but it is a factor that many people weigh when choosing a product type.
9. Dosage Considerations and Dose-Dependent Inhibition
One of the most important nuances in understanding CBD drug interactions is that enzyme inhibition isdose-dependent. This means that the risk and magnitude of an interaction increases as the CBD dose increases. A person taking 10 to 25 mg of CBD daily is in a fundamentally different pharmacokinetic situation than someone taking 200 to 1,500 mg daily, which is the range used in clinical epilepsy trials.
Much of the interaction data comes from the prescription cannabidiol clinical program, where patients received CBD at doses of 5 to 20 mg/kg/day. For a 70 kg adult, that translates to 350 to 1,400 mg per day. These are pharmaceutical-grade doses far exceeding what most consumers take as a supplement. The typical over-the-counter CBD user takes somewhere between 10 and 100 mg daily. Interaction data at these doses are limited, and individual variation (influenced by genetics, liver function, age, and other factors) means that lower doses could be clinically relevant for some people.
EFSA (2025) set a provisional safe intake of about 2 mg/day for healthy adults and could not establish safety for people taking any medication, in pregnancy or breastfeeding, or under 25. Many products on sale provide far more than that per serving.
10. Quality and Regulation Issues
The drug interaction question is complicated further by the reality that the CBD marketplace remains inconsistently regulated. Unlike prescription cannabidiol, which is manufactured under strict regulatory oversight with precise dosing, the vast majority of commercially available CBD products are sold as dietary supplements or hemp products, and they are not subject to the same manufacturing standards.
Independent laboratory analyses have consistently found significant discrepancies between label claims and actual CBD content. A 2017 study published in JAMA tested 84 CBD products purchased online and found that only31% were accurately labeled. Of the rest, 43% contained less CBD than stated, and 26% contained more. Perhaps most concerning, 21% of the products contained detectable levels of THC, including some products labeled as THC-free.
Follow-up analyses found similar issues, with some products containing contaminants including heavy metals, pesticides, and residual solvents. For someone trying to assess drug interaction risk, this variability is a significant problem. You cannot reliably predict the pharmacokinetic behavior of a product if you cannot be certain of its contents.
Third-party testing has emerged as the most practical solution. Reputable CBD manufacturers submit their products to independent laboratories that test for cannabinoid content (verifying the CBD and THC levels), contaminants, and potency. These results are typically available as Certificates of Analysis (COAs) on the manufacturer's website or by scanning a QR code on the product packaging. When choosing a CBD product, particularly one that will be used alongside prescription medications, verifying the COA is a reasonable precaution.
Look for products tested by ISO 17025-accredited laboratories, and check that the COA matches the specific batch number on your product. Third-party certification programs can provide an additional layer of quality assurance.
11. The Legal Landscape
The legal status of CBD varies considerably by jurisdiction, and this patchwork of regulation affects both product availability and quality standards. In the United States, the 2018 Farm Bill legalized hemp-derived CBD (containing less than 0.3% THC) at the federal level. However, the FDA has not approved CBD as a dietary supplement ingredient, creating a regulatory gray area. The agency has issued warning letters to companies making unsubstantiated health claims, but enforcement has been limited.
Individual U.S. states have their own regulations, and some have imposed additional restrictions on CBD sales, labeling, or THC content. In the European Union, CBD products are regulated under the Novel Food framework, which requires pre-market authorization (though enforcement timelines have varied); EFSA's 2025 provisional safe intake of about 2 mg/day informs those assessments. The UK's Food Standards Agency similarly regulates CBD as a novel food and publishes a list of products linked to novel food applications that are still pending; being on that list does not mean a product is authorised. In countries like Australia, CBD above certain doses (more than 150 mg per day) requires a prescription.
This regulatory fragmentation matters for the interaction question because it directly affects product quality and consistency. In jurisdictions with stronger regulatory frameworks, consumers generally have better assurance that products contain what they claim. In less regulated markets, the variability in CBD content, THC contamination, and overall product quality makes it harder to predict interaction risk.
It is also worth noting that drug testing policies in employment, sports, and legal contexts may be relevant for individuals using full-spectrum products. Even products containing less than 0.3% THC can, with regular use, accumulate enough THC metabolites to trigger a positive drug test. This is not a drug interaction in the pharmacological sense, but it is a practical consideration that often comes up alongside interaction discussions.
Sources & Further Reading
- Grayson L, et al. "An interaction between warfarin and cannabidiol, a case report." Epilepsy & Behavior Case Reports. 2018;9:10-11.
- Gaston TE, et al. "Interactions between cannabidiol and commonly used antiepileptic drugs." Epilepsia. 2017;58(9):1586-1592.
- Morrison G, et al. "Effect of cannabidiol on clobazam, N-desmethylclobazam, and valproate serum concentrations." Epilepsia. 2019;60(8):1605-1614.
- Nasrin S, et al. "Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes." Drug Metabolism and Disposition. 2021;49(3):261-270.
- Jadoon KA, et al. "A single dose of cannabidiol reduces blood pressure in healthy volunteers." JCI Insight. 2017;2(12):e93760.
- Bonn-Miller MO, et al. "Labeling accuracy of cannabidiol extracts sold online." JAMA. 2017;318(17):1708-1709.
- Prescription cannabidiol oral solution: US prescribing information (FDA) and EU summary of product characteristics (EMA).
- Leino AD, et al. "Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus." Am J Transplant. 2019;19(10):2944-2948.
- European Food Safety Authority (EFSA). "Provisional safe level for cannabidiol (CBD) as a novel food." 2025. efsa.europa.eu.
- Brown JD, Winterstein AG. "Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol use." J Clin Med. 2019;8(7):989.
This article synthesizes findings from peer-reviewed research, pharmacological databases, and clinical monographs. It is intended for educational purposes and does not constitute medical advice.
Check your specific combination
Enter CBD along with your current medications into our free Interaction Reference to see documented interactions.
Open Interaction Reference